AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 19 - (NewsRx.com & NewsRx.net) -- BioMedicines, Inc., announced that it has enrolled the first patients in its phase III clinical trial of Atamestane.
In this randomized, double-blind, placebo-controlled study, Atamestane will by administered as part of a two-drug combination hormonal therapy to treat women with metastatic breast cancer. To date, BioMedicines has qualified clinical sites in the United States, Canada, Russia, and the Ukraine.
"Our goal is to introduce a new standard of care for these patients," said Peter Langecker, MD, PhD, vice president of clinical affairs. "This study is designed to demonstrate that our Atamestane combination therapy is superior to current hormonal monotherapy."
Atamestane is an experimental drug that inhibits the growth of estrogen-dependent ...